Mouse pharmacological models of cognitive disruption relevant to schizophrenia

[1]  Adam L. Halberstadt,et al.  Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens , 2011, Neuropharmacology.

[2]  Kinzo Matsumoto,et al.  Ameliorative effects of yokukansan on learning and memory deficits in olfactory bulbectomized mice. , 2011, Journal of ethnopharmacology.

[3]  H. Meltzer,et al.  Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats , 2011, Psychopharmacology.

[4]  Y. Obara,et al.  Effects of Hericium erinaceus on amyloid β(25-35) peptide-induced learning and memory deficits in mice. , 2011, Biomedical research.

[5]  D. Souza,et al.  Caffeine prevents disruption of memory consolidation in the inhibitory avoidance and novel object recognition tasks by scopolamine in adult mice , 2010, Behavioural Brain Research.

[6]  A. Smit,et al.  Inhibitory control and response latency differences between C57BL/6J and DBA/2J mice in a Go/No-Go and 5-choice serial reaction time task and strain-specific responsivity to amphetamine , 2010, Behavioural Brain Research.

[7]  Shikha Snigdha,et al.  Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. , 2010, Pharmacology & therapeutics.

[8]  H. Moore.  The role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy. , 2010, Schizophrenia bulletin.

[9]  T. Nabeshima,et al.  Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems. , 2010, The international journal of neuropsychopharmacology.

[10]  D. Heck,et al.  Behavioral flexibility in a mouse model of developmental cerebellar Purkinje cell loss , 2010, Neurobiology of Learning and Memory.

[11]  R. Dias,et al.  Erythropoietin reverses the attentional set-shifting impairment in a rodent schizophrenia disease-like model , 2010, Psychopharmacology.

[12]  M. Geyer.  New Opportunities in the Treatment of Cognitive Impairments Associated With Schizophrenia , 2010 .

[13]  L. Saksida,et al.  Pharmacological or genetic inactivation of the serotonin transporter improves reversal learning in mice. , 2010, Cerebral cortex.

[14]  G. Barker,et al.  Changes in the Frontotemporal Cortex and Cognitive Correlates in First-Episode Psychosis , 2010, Biological Psychiatry.

[15]  D. Jeste,et al.  The mouse attentional-set-shifting task: A method for assaying successful cognitive aging? , 2010, Cognitive, affective & behavioral neuroscience.

[16]  D. Steffens,et al.  Cholinesterase Inhibitors as Adjunctive Therapy in Patients with Schizophrenia and Schizoaffective Disorder , 2010, CNS drugs.

[17]  J. Gogos,et al.  Cognition in mouse models of schizophrenia susceptibility genes. , 2010, Schizophrenia bulletin.

[18]  Vince D. Calhoun,et al.  Anomalous neural circuit function in schizophrenia during a virtual Morris water task , 2010, NeuroImage.

[19]  Sl McLean,et al.  Isolation rearing impairs novel object recognition and attentional set shifting performance in female rats , 2010, Journal of psychopharmacology.

[20]  A. Holmes,et al.  Predictably Irrational: Assaying Cognitive Inflexibility in Mouse Models of Schizophrenia , 2009, Frontiers in neuroscience.

[21]  E. Mohler,et al.  Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists. , 2010, Current pharmaceutical design.

[22]  M. Geyer,et al.  Prepulse inhibition and genetic mouse models of schizophrenia , 2009, Behavioural Brain Research.

[23]  J. Raber,et al.  Dihydrotestosterone modulates spatial working‐memory performance in male mice , 2009, Journal of neurochemistry.

[24]  Yuko Fujita,et al.  Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: Role of sigma-1 receptors , 2009, Brain Research.

[25]  J. Feldon,et al.  Are DBA/2 mice associated with schizophrenia-like endophenotypes? A behavioural contrast with C57BL/6 mice , 2009, Psychopharmacology.

[26]  Jared W. Young,et al.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. , 2009, Pharmacology & therapeutics.

[27]  D. Christensen,et al.  α7 Nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment , 2009, Neuropharmacology.

[28]  J. Vázquez-Barquero,et al.  Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. , 2009, The Journal of clinical psychiatry.

[29]  S. Beraki,et al.  Effects of repeated treatment of phencyclidine on cognition and gene expression in C57BL/6 mice. , 2009, The international journal of neuropsychopharmacology.

[30]  Hyoung‐Chun Kim,et al.  GABAB receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice. , 2009, European journal of pharmacology.

[31]  L. Saksida,et al.  Effects of Subchronic Phencyclidine (PCP) Treatment on Social Behaviors, and Operant Discrimination and Reversal Learning in C57BL/6J Mice , 2008, Front. Behav. Neurosci..

[32]  H. Geerts.  Bridging the Translational Disconnect in CNS Drug Discovery , 2009 .

[33]  J. Neill,et al.  Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT6 and 5-HT2A receptor mechanisms , 2009, Psychopharmacology.

[34]  Thomas Steckler,et al.  Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models , 2009, Neuropsychopharmacology.

[35]  Michael F. Green,et al.  Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. , 2009, Schizophrenia bulletin.

[36]  M. Behrens,et al.  Interleukin-6 Mediates the Increase in NADPH-Oxidase in the Ketamine Model of Schizophrenia , 2008, The Journal of Neuroscience.

[37]  B. Dean,et al.  Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? , 2008, Journal of neurochemistry.

[38]  Geoffrey Schoenbaum,et al.  Double Dissociation of the Effects of Medial and Orbital Prefrontal Cortical Lesions on Attentional and Affective Shifts in Mice , 2008, The Journal of Neuroscience.

[39]  M. Sarter,et al.  Detection of the Moderately Beneficial Cognitive Effects of Low-Dose Treatment with Haloperidol or Clozapine in an Animal Model of the Attentional Impairments of Schizophrenia , 2008, Neuropsychopharmacology.

[40]  Eiki Takahashi,et al.  Improved short-term memory and increased expression of NR2B observed in senescence-accelerated mouse (SAM) P6 , 2008, Experimental Gerontology.

[41]  Franz X Vollenweider,et al.  Serotonin research: contributions to understanding psychoses. , 2008, Trends in pharmacological sciences.

[42]  A. Terry Jr..  Role of the Central Cholinergic System in the Therapeutics of Schizophrenia , 2008, Current Neuropharmacology.

[43]  T. George,et al.  Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia , 2008, Schizophrenia Research.

[44]  J. Lieberman,et al.  Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. , 2008, The American journal of psychiatry.

[45]  A. Kuzmin,et al.  Repeated low dose of phencyclidine administration impairs spatial learning in mice: Blockade by clozapine but not by haloperidol , 2008, European Neuropsychopharmacology.

[46]  K. Willecke,et al.  Connexin31.1 deficiency in the mouse impairs object memory and modulates open-field exploration, acetylcholine esterase levels in the striatum, and cAMP response element-binding protein levels in the striatum and piriform cortex , 2008, Neuroscience.

[47]  Herbert Y Meltzer,et al.  Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial , 2008, Neuropsychopharmacology.

[48]  G. Weniger,et al.  Allocentric memory impaired and egocentric memory intact as assessed by virtual reality in recent-onset schizophrenia , 2008, Schizophrenia Research.

[49]  C. Schmauss,et al.  Induction of early growth response gene 2 expression in the forebrain of mice performing an attention-set-shifting task , 2008, Neuroscience.

[50]  R. Dias,et al.  Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat—a back translational study , 2008, Psychopharmacology.

[51]  T. Nabeshima,et al.  Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors , 2008, Psychopharmacology.

[52]  James M Gold,et al.  Galantamine for the treatment of cognitive impairments in people with schizophrenia. , 2008, The American journal of psychiatry.

[53]  Hyoung‐Chun Kim,et al.  Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice , 2008, Psychopharmacology.

[54]  J. M. Silvers,et al.  Automation of the novel object recognition task for use in adolescent rats , 2007, Journal of Neuroscience Methods.

[55]  H. Schiöth,et al.  The G protein-coupled receptor subset of the rat genome , 2007, BMC Genomics.

[56]  S. Mosolov,et al.  Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.

[57]  C. Carter,et al.  Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. , 2007, Schizophrenia bulletin.

[58]  J. Lieberman,et al.  Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. , 2007, Schizophrenia bulletin.

[59]  M. Loos,et al.  Strain specificity and cholinergic modulation of visuospatial attention in three inbred mouse strains , 2007, Genes, brain, and behavior.

[60]  Peter B. Jones,et al.  First- vs Second-Generation Antipsychotic Drugs in Schizophrenia—Reply , 2007 .

[61]  J. Mintz,et al.  CUtLASS confirms CATIE. , 2007, Archives of general psychiatry.

[62]  Z. Nahas,et al.  Double-blind donepezil–placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: A pilot study , 2007, Schizophrenia Research.

[63]  Michael F. Green,et al.  Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.

[64]  Jung-Goo Lee,et al.  A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia , 2007, Journal of psychopharmacology.

[65]  R. Heinrichs.  Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.

[66]  T. Suppes,et al.  Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study , 2007, Acta psychiatrica Scandinavica.

[67]  G. Barker,et al.  Recognition Memory for Objects, Place, and Temporal Order: A Disconnection Analysis of the Role of the Medial Prefrontal Cortex and Perirhinal Cortex , 2007, The Journal of Neuroscience.

[68]  T. Nabeshima,et al.  Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model , 2007, Neuropharmacology.

[69]  Yuko Fujita,et al.  Phencyclidine-Induced Cognitive Deficits in Mice are Improved by Subsequent Subchronic Administration of Fluvoxamine: Role of Sigma-1 Receptors , 2007, Neuropsychopharmacology.

[70]  R. Godbout,et al.  Rivastigmine treatment as an add‑on to antipsychotics in patients with schizophrenia and cognitive deficits , 2007, Current medical research and opinion.

[71]  H. Lublin,et al.  Effects of Donepezil Adjunctive Treatment to Ziprasidone on Cognitive Deficits in Schizophrenia: A Double-blind, Placebo-Controlled Study , 2007, Clinical neuropharmacology.

[72]  A. Megens,et al.  Attentional performance of (C57BL/6J×129Sv)F2 mice in the five-choice serial reaction time task , 2006, Physiology & Behavior.

[73]  Yuko Fujita,et al.  Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of alpha7 nicotinic receptors. , 2006, European journal of pharmacology.

[74]  S. Gauthier,et al.  Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. , 2006, Journal of psychiatry & neuroscience : JPN.

[75]  M. Sarter.  Preclinical research into cognition enhancers. , 2006, Trends in pharmacological sciences.

[76]  Peter B. Jones,et al.  Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). , 2006, Archives of general psychiatry.

[77]  M. Geyer,et al.  The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats , 2006, Psychopharmacology.

[78]  Keith A. Young,et al.  Galantamine Improves Cognition in Schizophrenic Patients Stabilized on Risperidone , 2006, Biological Psychiatry.

[79]  B. Pouzet,et al.  Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: Deficits induced by scopolamine and by prolonging the retention interval , 2006, Pharmacology Biochemistry and Behavior.

[80]  Lisa M. Saksida,et al.  Genetic and dopaminergic modulation of reversal learning in a touchscreen-based operant procedure for mice , 2006, Behavioural Brain Research.

[81]  T. Sharma,et al.  Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind investigation , 2006, Schizophrenia Research.

[82]  H. Gu,et al.  Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs , 2006, BMC pharmacology.

[83]  Robert C. Smith,et al.  Effects of Nicotine Nasal Spray on Cognitive Function in Schizophrenia , 2006, Neuropsychopharmacology.

[84]  G. Kiosseoglou,et al.  Neuropsychological profile of cognitively impaired patients with schizophrenia. , 2006, Comprehensive psychiatry.

[85]  H. Taukulis,et al.  Impairment of single-trial memory formation by oral methylphenidate in the rat , 2006, Neurobiology of Learning and Memory.

[86]  M. Geyer.  Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia? , 2006, Dialogues in clinical neuroscience.

[87]  S. Marder.  The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia , 2006, Dialogues in clinical neuroscience.

[88]  D. Paleacu,et al.  Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study , 2006, International Psychogeriatrics.

[89]  Stefan Leucht,et al.  Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. , 2006, The American journal of psychiatry.

[90]  Jeffrey A. Lieberman,et al.  Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis , 2006, Biological Psychiatry.

[91]  T. Nabeshima,et al.  Repeated Methamphetamine Treatment Impairs Recognition Memory Through a Failure of Novelty-Induced ERK1/2 Activation in the Prefrontal Cortex of Mice , 2006, Biological Psychiatry.

[92]  Peter B. Jones,et al.  Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. , 2005, Schizophrenia bulletin.

[93]  Michael F. Green,et al.  Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. , 2006, The Journal of clinical psychiatry.

[94]  F. Joseph McClernon,et al.  Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization , 2006, Psychopharmacology.

[95]  J. Lieberman,et al.  The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome , 2005, Schizophrenia Research.

[96]  J. Csernansky,et al.  Cholinesterase Inhibitors Ameliorate Behavioral Deficits Induced by MK-801 in Mice , 2005, Neuropsychopharmacology.

[97]  Philip D. Harvey,et al.  Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. , 2005, The American journal of psychiatry.

[98]  L. Saksida,et al.  Discrimination of multidimensional visual stimuli by mice: intra- and extradimensional shifts. , 2005, Behavioral neuroscience.

[99]  H. Meziane,et al.  Working memory deficits in retinoid X receptor gamma-deficient mice. , 2005, Learning & memory.

[100]  E. Bora,et al.  The Effect of Galantamine Added to Clozapine on Cognition of Five Patients With Schizophrenia , 2005, Clinical neuropharmacology.

[101]  A. Tort,et al.  Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice , 2005, Behavioural pharmacology.

[102]  G. Dawson,et al.  Assessment of modafinil on attentional processes in a five-choice serial reaction time test in the rat , 2005, Journal of psychopharmacology.

[103]  E. Murphy,et al.  PDE10A inhibition reverses subchronic PCP‐induced deficits in attentional set‐shifting in rats , 2005, The European journal of neuroscience.

[104]  S. B. Caine,et al.  Dopamine D1 and D2 Agonist Effects on Prepulse Inhibition and Locomotion: Comparison of Sprague-Dawley Rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.

[105]  A. Grace,et al.  Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. , 2005, Schizophrenia bulletin.

[106]  Cameron S Carter,et al.  Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia. , 2005, Schizophrenia bulletin.

[107]  Michael F. Green,et al.  A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. , 2005, Schizophrenia bulletin.

[108]  Brian J. Morris,et al.  Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia , 2005, Psychopharmacology.

[109]  M. Carli,et al.  Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGLU2/3 receptor agonist LY379268 , 2005, Psychopharmacology.

[110]  Martin Sarter,et al.  Animal cognition: defining the issues , 2004, Neuroscience & Biobehavioral Reviews.

[111]  W. Fenton,et al.  Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia , 2004, Schizophrenia Research.

[112]  M. Kotler,et al.  Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living , 2004, International clinical psychopharmacology.

[113]  D. Javitt,et al.  Glutamate as a therapeutic target in psychiatric disorders , 2004, Molecular Psychiatry.

[114]  A. Phillips,et al.  Medial prefrontal cortex is involved in spatial temporal order memory but not spatial recognition memory in tests relying on spontaneous exploration in rats , 2004, Behavioural Brain Research.

[115]  A. Sleight,et al.  5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation—an effect sensitive to NMDA receptor antagonism , 2004, Neuropharmacology.

[116]  R. Stackman,et al.  On the delay-dependent involvement of the hippocampus in object recognition memory , 2004, Neurobiology of Learning and Memory.

[117]  Rosemary A. Cowell,et al.  Double Dissociation between the Effects of Peri-Postrhinal Cortex and Hippocampal Lesions on Tests of Object Recognition and Spatial Memory: Heterogeneity of Function within the Temporal Lobe , 2004, The Journal of Neuroscience.

[118]  Aaron L Mishara,et al.  A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book , 2004, Biological Psychiatry.

[119]  A. Phillips,et al.  Interaction between Perirhinal and Medial Prefrontal Cortex Is Required for Temporal Order But Not Recognition Memory for Objects in Rats , 2004, The Journal of Neuroscience.

[120]  P. Kelly,et al.  Habenula lesions cause impaired cognitive performance in rats: implications for schizophrenia , 2004, The European journal of neuroscience.

[121]  J. Podhorná,et al.  Subchronic phencyclidine treatment impairs performance of C57BL/6 mice in the attentional set-shifting task , 2004, Behavioural pharmacology.

[122]  J. Friedman,et al.  Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists , 2004, Psychopharmacology.

[123]  Steven G Potkin,et al.  Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia , 2004, Schizophrenia Research.

[124]  P. Francis,et al.  Cholinesterase Inhibitors Used in the Treatment of Alzheimer’s Disease , 2004, Drugs & aging.

[125]  Robert Freedman,et al.  Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia , 2004, Psychopharmacology.

[126]  A. Oliverio,et al.  Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits , 2003, Behavioural pharmacology.

[127]  G. Higgins,et al.  Phencyclidine Exacerbates Attentional Deficits in a Neurodevelopmental Rat Model of Schizophrenia , 2003, Neuropsychopharmacology.

[128]  N. Swerdlow,et al.  Dopamine depletion of the nucleus accumbens reverses isolation-induced deficits in prepulse inhibition in rats , 2003, Neuroscience.

[129]  M. Geyer,et al.  Low dose ketamine increases prepulse inhibition in healthy men , 2003, Neuropharmacology.

[130]  Alexander L. Miller,et al.  The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. , 2003, The Journal of clinical psychiatry.

[131]  P. McGuffin,et al.  Can the social environment cause schizophrenia? , 2003, British Journal of Psychiatry.

[132]  Michael F. Green,et al.  Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study , 2003, Psychopharmacology.

[133]  Diogo R. Lara,et al.  Chronic treatment with caffeine blunts the hyperlocomotor but not cognitive effects of the N-methyl-d-aspartate receptor antagonist MK-801 in mice , 2003, Psychopharmacology.

[134]  Robert W. Buchanan,et al.  An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia , 2003, Schizophrenia Research.

[135]  Abraham Weizman,et al.  Beneficial Effect of Donepezil Augmentation for the Management of Comorbid Schizophrenia and Dementia , 2003, Clinical neuropharmacology.

[136]  M. Geyer,et al.  Dopamine D1 Rather than D2 Receptor Agonists Disrupt Prepulse Inhibition of Startle in Mice , 2003, Neuropsychopharmacology.

[137]  Bob Oranje,et al.  Modulating sensory gating in healthy volunteers The effects of ketamine and haloperidol , 2002, Biological Psychiatry.

[138]  M. Low,et al.  Differential Effects of Direct and Indirect Dopamine Agonists on Prepulse Inhibition: A Study in D1 and D2 Receptor Knock-Out Mice , 2002, The Journal of Neuroscience.

[139]  D. Bilkey,et al.  The effects of NMDA lesions centered on the postrhinal cortex on spatial memory tasks in the rat. , 2002, Behavioral neuroscience.

[140]  T. Robbins,et al.  The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry , 2002, Psychopharmacology.

[141]  Michael F. Green,et al.  The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone , 2002, Biological Psychiatry.

[142]  H. Emrich,et al.  Short-Term Cognitive Improvement in Schizophrenics Treated with Typical and Atypical Neuroleptics , 2002, Neuropsychobiology.

[143]  Alexander L. Miller,et al.  Does cognitive function improve with quetiapine in comparison to haloperidol? , 2002, Schizophrenia Research.

[144]  H. Phillips,et al.  Hippocampal dysfunction and behavioral deficit in the water maze in mice: An unresolved issue? , 2002, Brain Research Bulletin.

[145]  Dennis S. Charney,et al.  Neuropsychopharmacology : The Fifth Generation of Progress , 2002 .

[146]  M. Geyer.  33 THE ROLE OF PRECLINICAL MODELS IN THE DEVELOPMENT OF PSYCHOTROPIC DRUGS , 2002 .

[147]  L. Saksida,et al.  Discrimination of computer-graphic stimuli by mice: a method for the behavioral characterization of transgenic and gene-knockout models. , 2001, Behavioral Neuroscience.

[148]  R. D'Hooge,et al.  Applications of the Morris water maze in the study of learning and memory , 2001, Brain Research Reviews.

[149]  A. Malla,et al.  Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. , 2001, Journal of psychiatry & neuroscience : JPN.

[150]  Philip D. Harvey,et al.  Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. , 2001, The American journal of psychiatry.

[151]  E. Richelson,et al.  Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. , 2000, Life sciences.

[152]  G D Pearlson,et al.  Neurobiology of schizophrenia , 2000, Annals of neurology.

[153]  B. Yee.  Cytotoxic lesion of the medial prefrontal cortex abolishes the partial reinforcement extinction effect, attenuates prepulse inhibition of the acoustic startle reflex and induces transient hyperlocomotion, while sparing spontaneous object recognition memory in the rat , 1999, Neuroscience.

[154]  U. Kläning.  Greater occurrence of schizophrenia in dizygotic but not monozygotic twins , 1999, British Journal of Psychiatry.

[155]  L. Wilkinson,et al.  Visuospatial attentional functioning in mice: interactions between cholinergic manipulations and genotype , 1999, The European journal of neuroscience.

[156]  R. Roth,et al.  The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia , 1999, Neuropsychopharmacology.

[157]  J. Lieberman,et al.  The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. , 1999, Schizophrenia bulletin.

[158]  S. Marder,et al.  Risperidone versus haloperidol on secondary memory: can newer medications aid learning? , 1999, Schizophrenia bulletin.

[159]  R. Roth,et al.  Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats , 1998, Neuroscience Letters.

[160]  Michael F. Green,et al.  Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients , 1998, Biological Psychiatry.

[161]  A. Malhotra,et al.  Clozapine Blunts N-Methyl-d-Aspartate Antagonist-Induced Psychosis: A Study with Ketamine , 1997, Biological Psychiatry.

[162]  Anil K Malhotra,et al.  Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics , 1997, Neuropsychopharmacology.

[163]  J. Dodart,et al.  Scopolamine‐induced deficits in a two‐trial object recognition task in mice , 1997, Neuroreport.

[164]  N. Andreasen,et al.  Diagnosis, methodology and subtypes of schizophrenia. , 1997, Neuropsychobiology.

[165]  A. C. Collins,et al.  Genetic Correlation of Inhibitory Gating of Hippocampal Auditory Evoked Response and α-Bungarotoxin-Binding Nicotinic Cholinergic Receptors in Inbred Mouse Strains , 1996, Neuropsychopharmacology.

[166]  Herbert Weingartner,et al.  NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers , 1996, Neuropsychopharmacology.

[167]  Michael F. Green,et al.  What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.

[168]  D.N.C. Jones,et al.  Age-associated impairments in a test of attention: evidence for involvement of cholinergic systems , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[169]  Jane S. Paulsen,et al.  Distinct cognitive profiles of cortical and subcortical dementia in advanced illness , 1995, Neurology.

[170]  J. D. Bruin,et al.  A behavioural analysis of rats with damage to the medial prefrontal cortex using the morris water maze: evidence for behavioural flexibility, but not for impaired spatial navigation , 1994, Brain Research.

[171]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[172]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[173]  D L Braff,et al.  Sensorimotor gating and schizophrenia. Human and animal model studies. , 1990, Archives of general psychiatry.

[174]  P. Appelbaum,et al.  Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. , 1990, Schizophrenia bulletin.

[175]  M. Strauss,et al.  Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. , 1989, Journal of abnormal psychology.

[176]  T. Robbins,et al.  Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal , 1983, Behavioural Brain Research.

[177]  R. Morris,et al.  Place navigation impaired in rats with hippocampal lesions , 1982, Nature.

[178]  L A Leavitt,et al.  Lead-stimulation effects of human cardiac orienting and blink reflexes. , 1975, Journal of experimental psychology. Human perception and performance.